Leukemia Research
Volume 29, Issue 8 , Pages 961-966 , August 2005

Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation

  • Sara Galimberti

      Affiliations

    • Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara-Via Roma, 56-56100 Pisa, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 050992815; fax: +39 050830162.
    • ,
  • Edoardo Benedetti

      Affiliations

    • Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara-Via Roma, 56-56100 Pisa, Italy
    • ,
  • Fortunato Morabito

      Affiliations

    • Bone Marrow Transplant Unit, Hematology Department, A.O. Reggio Calabria, Italy
    • ,
  • Federico Papineschi

      Affiliations

    • Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara-Via Roma, 56-56100 Pisa, Italy
    • ,
  • Vincenzo Callea

      Affiliations

    • Hematology Unit, Hematology Department, A.O. Reggio Calabria, Italy
    • ,
  • Rita Fazzi

      Affiliations

    • Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara-Via Roma, 56-56100 Pisa, Italy
    • ,
  • Caterina Stelitano

      Affiliations

    • Hematology Unit, Hematology Department, A.O. Reggio Calabria, Italy
    • ,
  • Francesca Andreazzoli

      Affiliations

    • Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara-Via Roma, 56-56100 Pisa, Italy
    • ,
  • Francesca Guerrini

      Affiliations

    • Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara-Via Roma, 56-56100 Pisa, Italy
    • ,
  • Elena Ciabatti

      Affiliations

    • Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara-Via Roma, 56-56100 Pisa, Italy
    • ,
  • Massimo Martino

      Affiliations

    • Bone Marrow Transplant Unit, Hematology Department, A.O. Reggio Calabria, Italy
    • ,
  • Francesco Nobile

      Affiliations

    • Hematology Unit, Hematology Department, A.O. Reggio Calabria, Italy
    • ,
  • Pasquale Iacopino

      Affiliations

    • Bone Marrow Transplant Unit, Hematology Department, A.O. Reggio Calabria, Italy
    • ,
  • Mario Petrini

      Affiliations

    • Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara-Via Roma, 56-56100 Pisa, Italy

Received 27 September 2004 ,Accepted 22 January 2005.

References 

  1. Corradini P, Voena C, Tarella C, Blade’ J, Samson D, Reece D, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. JCO. 1999;17:208–215
  2. Barbui AM, Galli M, Dotti G, Belli N, Borleri G, Gritti G, et al. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol. 2002;116:202–210
  3. Galimberti S, Morabito F, Guerrini F, Palumbo GA, Azzara’ A, Martino M, et al. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol. 2003;120:405–412
  4. Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagna E, Tosi P, et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood. 2002;96:355–357
  5. Gahrton G, Tura S, Ljungmann P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med. 1991;325:1267–1273
  6. Besinger WI, Buckner CD, Anasetti C, Clift R, Storb R, Barnett T, et al. Allogeneic bone marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88:2787–2793
  7. Perez-Simon JA, Martino R, Allegre A, Tomas JF, De Leon A, Caballero D, et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol. 2003;121:104–108
  8. Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol. 2003;121:411–418
  9. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447–3454
  10. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remission in patients with poor-risk hematologic malignancies. Blood. 2002;99:75–82
  11. Blade’ J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. Br J Haematol. 1998;102:1115–1123
  12. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854
  13. Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004;104:2254–2262
  14. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–259
  15. Reed TJ, Reid A, Wallberg K, O’Leary J, Frizzera G. Determination of B-cell clonality in paraffin-embedded lymphnodes using the polymerase chain reaction. Diagn Mol Pathol. 1993;2:42–49
  16. Ritter JH, Wick MR, Adesokan PN, Fitzgibbon JF, Zhu X, Humphrey PA. Assessment of clonality in cutaneous lymphoid infiltrates by polymerase chain reaction analysis of immunoglobulin heavy chain gene rearrangement. Am J Clin Pathol. 1997;108:60–68
  17. Willems P, Verhagen O, Segeren C, Veenhuizen P, Guikema J, Wiemer E, et al. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Blood. 2000;96:63–70
  18. Thiede C, Bornhauser M, Oelschlagel U, Brendel C, Leo R, Daxberger H, et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia. 2001;15:293–302
  19. Kulkarni S, Powles RL, Trleaven JG, Singhal S, Saso R, Horton C, et al. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma. Bone Marrow Transplant. 1999;23:675–680
  20. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. JCO. 2000;18:2273–2281
  21. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in multiple myeloma. Blood. 2003;102:1927–1929
  22. Luft T, Moos M, Goldsmidt H, Ho AD, Gorner M. Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. Br J Haematol. 2003;123:646–653
  23. O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–386
  24. Van Tol MJ, Gerritsen EJ, De Lange GG, van Leeuwen AM, Jol van der Zijde CM. The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. Blood. 1996;87:818–826
  25. Rubio MT, Kim YM, Mapara M, Zhao G, Sykes M. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-γ. Blood. 2003;102:2300–2337

PII: S0145-2126(05)00064-0

doi: 10.1016/j.leukres.2005.01.017

Leukemia Research
Volume 29, Issue 8 , Pages 961-966 , August 2005

Article Tools

* Image Usage & Resolution